Natco Pharma Ltd.

Financial

	Natco Pharma	Sanofi India	Jubilant Pharmova
Operational Metrics
API Sector
US DMF Filings	58.0 .	n/a	98.0 .
Pharmaceutical Sector
Number of ANDA's Filed in USA	51.0 .	n/a	100.0 .
Number of ANDA's Approved By USFDA	41.0 .	n/a	62.0 .
Domestic Sales Growth - YoY	31.2 %	0.6 %	n/a
R&D as a % of Total Sales	7.6 %	0.0	0.33 %
Financials
5 yr Average ROE	13.06 %	43.25 %	8.35 %
5yr average Equity Multiplier	1.18	3.33	2.0
5yr Average Asset Turnover Ratio	0.46	0.52	0.59
5yr Avg Net Profit Margin	23.09 %	25.25 %	7.13 %
Price to Book	2.12	17.22	2.48
P/E	8.12	35.86	23.47
5yr Avg Cash Conversion Cycle	10.54 Days	24.48 Days	-19.21 Days
Inventory Days	99.95 Days	66.8 Days	81.78 Days
Days Receivable	86.16 Days	31.98 Days	51.11 Days
Days Payable	154.15 Days	63.37 Days	173.51 Days
5yr Average Interest Coverage Ratio	46.61	906.11	3.98
5yr Avg ROCE	16.05 %	25.91 %	9.05 %
5yr Avg Operating Profit Margin	30.17 %	25.97 %	18.69 %
5 yr average Debt to Equity	0.06	0.0	0.64
5yr CAGR Net Profit	24.68 %	31.63 %	-38.8 %
5yr Average Return on Assets	11.07 %	13.01 %	4.23 %
Shareholdings
Promoter Holding	49.56 %	60.4 %	50.68 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.75 %	0.0	0.0
Change in Mutual Fund Holding (3 Yrs)	-5.54 %	1.07 %	3.61 %

Business

	Natco Pharma	Sanofi India	Jubilant Pharmova
Product Wise Break-Up	Product Wise Break-Up Formulations 59.0 Active Pharmaceutical Ingredient (API) 10.0 Crop Protection 2.0 Pharmaceuticals 0 0 Radiopharmaceuticals 0 Allergy therapy products 0 Active pharmaceutical ingredients 0 India Branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 0 Solid dosage formulations 0 Others 29.0	Product Wise Break-Up Formulations 0 Crop Protection 0 0 Allergy therapy products 0 India Branded pharmaceuticals 0 0 Active pharmaceutical ingredients 0 Solid dosage formulations 0 Pharmaceutical 100.0 Radiopharmaceuticals 0 Specialty intermediates 0 Active Pharmaceutical Ingredient (API) 0 Life science chemicals 0 Nutritional products 0	Product Wise Break-Up Formulations 0 Crop Protection 0 Contract Manufacturing 16.81 Anti-allergic 10.21 India branded pharmaceuticals 0.72 Contract Research and Development Services 6.7 Active Pharmaceutical Ingredient (API) 9.26 Solid dosage formulations 10.82 Pharmaceuticals 0 Radiopharmaceuticals 44.9 Specialty intermediates 0 Active Pharmaceutical Ingredient (API) 0 Life science chemicals 0 Nutritional products 0 Others 0.58
Segment Break-Up	Segment Break-Up Pharmaceuticals 96.82 Agrochemicals 3.18 CDMO Sterile Injectables 0 Generics 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 0 Life Science Ingredients 0	-	Segment Break-Up Life Science Ingredients 0 Proprietary Novel Drugs 0 Drug discovery and development solutions 16.33 Radiopharma 45.97 Generics 10.91 CDMO Sterile Injectables 17.28 Pharmaceuticals 0 Allergy Immunotherapy 9.51 Agrochemicals 0
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Oncology 58.79 RESPIRATORY 0 DERMA 0 ANTI-INFECTIVES 0 GASTRO INTESTINAL 0 NEURO/CNS 0 PAIN/ANALGES 0 CARDIAC 0 ANTI DIABETIC 0 VMN 0 Others 41.21	Therapeutic Area Wise Break-Up - Domestic Pain Management 7.15 Oncology 0 Cardiac Science 17.42 Anti - Diabetes 38.81 Gastro Intestinal 10.56 Respiratory Systems 13.48 DERMA 0 VMN 0 Anti-Infective 5.72 Central Nervous System (CNS) 6.86	-
Location Wise Break-Up	Location Wise Break-Up USA 70.49 Rest of the World 15.24 India 14.27 Singapore 0 China 0 Americas and Europe 0	Location Wise Break-Up Americas and Europe 0 China 0 India 81.47 USA 0 Singapore 17.88 Rest of the World 0 Others 0.65	Location Wise Break-Up Americas and Europe 90.17 China 0 India 2.33 USA 0 Singapore 0 Rest of the World 7.5
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 100.0 Agrochemicals 0 Generics 0 CDMO Sterile Injectables 0 Allergy Immunotherapy 0 Radiopharma 0 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0	-	Operating Profit Break-Up Life Science Ingredients 0 Proprietary Novel Drugs 0 Radiopharma 41.47 Generics 8.2 CDMO Sterile Injectables 14.56 Pharmaceuticals 0 Allergy Immunotherapy 20.39 Contract Research and Development 15.39 Agrochemicals 0
Asset Break-Up	Asset Break-Up Pharmaceuticals 92.5 Agrochemicals 7.5 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0	-	Asset Break-Up Life Science Ingredients 0 Proprietary Novel Drugs 2.16 Pharmaceuticals 0 Contract Research and Development 12.96 Agrochemicals 0 Others 84.88

Natco Pharma Ltd.

SIGN UP FOR FREE